# Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

> **NCT03352427** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Glioma
- High Grade Glioma
- Pontine Tumors

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT03352427
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-06
- **Primary completion:** 2019-04-17
- **Final completion:** 2019-05-15
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2022-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03352427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03352427, "Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT03352427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*